Publication | Closed Access

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)

Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaMalignant Blood DisorderImmunologyHematologyPharmacotherapyIntensive ChemotherapyMetronomic ChemotherapyImmunotherapyMedicineMyelodysplastic SyndromesMyeloid Neoplasia